Xylem's stock has fallen over 30% year-to-date after missing Q3 2026 revenue and EPS expectations. The company lowered its full-year 2026 guidance, projecting revenue of $8.95 billion and EPS between $5.40 and $5.45 due to project delays and weak sales. Despite these challenges, Xylem's backlog grew 13% year-over-year to $5.5 billion, with strong orders in Applied Water and Measurement & Control Solutions segments. The stock now trades at a significant discount, with an expected long-term return above 25%, leading to a Buy rating from the analyst.
Xylem's stock price stands at USD 91.55 on Pluang as of Oct 28, 2026 19:11 WIB, showing a 1.41% decline in the past day. Despite the recent revenue and EPS setbacks reported in the news, Pluang investors demonstrate strong confidence with 97% Buy order activity and a typical hold time of 51 days. The stock's market cap is $21.30 billion, indicating significant investor interest amid the ongoing challenges.
